Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

Table 2 TS-1 dose modification and compliance of patients with gastric cancer

	n (%)
Received treatment schedule modification	18 (45)
Underwent dose de-escalation	6 (15)
Discontinued TS-1 treatment at study end	31 (77.5)
Reasons for discontinuation
Completion of TS-1 treatment	14 out of 31 (45)
Toxicity	9 out of 31 (29)
Tumor recurrence	6 out of 31 (19)
Economic factors	2 out of 31 (6)
TS-1 treatment duration (compliance)
At least 3 months	30 out of 38 (78.9)
At least 6 months	26 out of 35 (74.3)
At least 9 months	18 out of 29 (62.1)
Completed nine full cycles	14 out of 25 (56)

The median TS-1 treatment duration was 226 days (range 7 to 400). TS-1 compliance: the number of patients who discontinued treatment because of toxicity or economic factor subtracted from the number of patients who underwent TS-1 treatment at the given time. Patients who withdrew from TS-1 treatment owing to tumor relapse were excluded in the TS-1 compliance calculation for any given time.

ISSN: 1477-7819